Andrew A. F. Hack - 26 May 2023 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role: Director
Signature: /s/ Andrew Hack
Issuer symbol: DVAX
Transactions as of: 26 May 2023
Net transactions value: $0
Form type: 4
Filing time: 31 May 2023, 17:43:23 UTC
Previous filing: 19 May 2023
Next filing: 12 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DVAX	Common Stock	Award	$0	+5,357	+100%	$0.000000	10,714	26 May 2023	Direct	F1, F2
holding	DVAX	Common Stock						2,915,000	26 May 2023	See footnotes	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DVAX	Stock Option (Right to Buy)	Award	$0	+22,500		$0.000000	22,500	26 May 2023	Common Stock	22,500	$11.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company.
F2	The Reporting Person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes 5,357 newly awarded RSUs and 5,357 RSUs previously reported in Table II.
F3	This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.
F4	Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
F5	Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.